troglitazone has been researched along with Aortic Diseases in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goetze, S | 1 |
| Kintscher, U | 1 |
| Kim, S | 1 |
| Meehan, WP | 1 |
| Kaneshiro, K | 1 |
| Collins, AR | 1 |
| Fleck, E | 1 |
| Hsueh, WA | 1 |
| Law, RE | 1 |
1 other study available for troglitazone and Aortic Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
Topics: Animals; Aortic Diseases; Cell Adhesion; Cell Movement; Cell Nucleus; Cells, Cultured; Chromans; Cyt | 2001 |